01.08.25 -- A Realistic Look At What RFK Jr. Could Mean For FDA

To drive forward the promising pipeline of breakthrough therapies while curbing costs, industry futurists are putting their bets on technological advancements and GenAI to reshape the drug development life cycle. This session is an invitation to rethink traditional approaches, consider innovative risk mitigation strategies, and envision a future where clinical trials are faster and more efficient but also potentially free from human limitations. Register here.

Ensuring optimal yield for engineered viral vectors early in a process is crucial to ensuring their eventual commercial viability and broader patient accessibility.

Explore how the various proprietary platforms and in-house expertise fit together to enable a range of comprehensive options that can be adapted to fit development strategies.

Dysphagia impacts treatment compliance and disproportionately affects the elderly. Learn how microencapsulation enabled formulation of a water-soluble powder drives patient adherence.

AI has great potential to enhance the efforts of your team members by accelerating data interactions. Watch this webinar to discover how AI can improve clinical trial outcomes and data management.

Middlesex County, NJ, offers life sciences organizations a deep talent pool, an extensive R&D presence, and dedicated backing by local government investment.